EuroPCR 2021 | Evolut Low Risk: Two-Year Results of The Self-Expanding Valve in Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) with the Evolut self-expanding valve was non-inferior to surgery in patients with low surgical risk. After two years, the primary endpoint of death or disabling stroke was similar between both strategies.

Evolut Low Risk

This presentation at EuroPCR 2021 reinforces the results presented during the American College of Cardiology (ACC) 2019 Congress and published in the New England Journal of Medicine (NEJM). At the time, a Bayesian analysis had been performed to estimate two-year outcomes when 850 of the 1414 patients included had reached only one year of follow-up.

All patients have now reached two years of follow-up and the plan is to extend the follow-up to 10 years.

After two years, the primary endpoint (all-cause mortality and disabling stroke) was observed in 4.3% of those who underwent TAVR vs. 6.3% of those who underwent surgery. This difference was not statistically significant, which confirms non-inferiority—albeit non-superiority.

When considering the endpoints separately, we see that all-cause mortality was 3.5% vs. 4.4% (p = 0.366), and disabling stroke was 1.5% vs. 2.7% (= 0.11).

Differences were found in the need of permanent pacemaker, regarding which surgery was better (21.1% for TAVR vs. 7.9% for surgery).


Read also: EuroPCR 2021 | Ultrathin Struts Consolidate as Next DES Development.


Over these two years, better implantation techniques were developed using Evolut, such as overlapping the valves, which could reduce the difference. Something similar happens with paravalvular leak, regarding which surgery was superior (mild leaks: 26.6% for TAVR vs. only 2.6% for surgery; p < 0.001). However, the same technique refinement that improved the need for pacemaker also had an impact on leaks.

In terms of valve hemodynamics, Evolut had lower gradients and larger valvular areas than surgical ones.

Original Title: Complete 2-year follow-up from the Evolut low risk trial.

Reference: Presentado por Forrest J. en el EuroPCR 2021.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

Moderate to severe mitral valve regurgitation (MR) continues is still a high prevalence condition with bad prognosis, particularly among the elderly with left ventricular...

Impact of Balloon Post-Dilation on the Long-Term Durability of Bioprostheses after TAVR

Balloon post-dilation (BPD) during transcatheter aortic valve replacement (TAVR) allows for the optimization of prosthesis expansion and the reduction of residual paravalvular aortic regurgitation....

TAVR in Pure Native Aortic Regurgitation: Are Dedicated Devices Truly Superior?

This systematic meta-analysis assessed the efficacy and safety of transcatheter aortic valve replacement (TAVR) in patients with pure native aortic regurgitation. The emergence of...

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

Moderate to severe mitral valve regurgitation (MR) continues is still a high prevalence condition with bad prognosis, particularly among the elderly with left ventricular...

EMERALD II: Non-Invasive Coronary Anatomy and Physiology (CCTA) in ACS Prediction

Despite steady progress in secondary prevention and medical treatment optimization (OMT), acute coronary syndrome (ACS) remains one of the leading causes of cardiovascular morbimortality....

Impact of Balloon Post-Dilation on the Long-Term Durability of Bioprostheses after TAVR

Balloon post-dilation (BPD) during transcatheter aortic valve replacement (TAVR) allows for the optimization of prosthesis expansion and the reduction of residual paravalvular aortic regurgitation....